X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Be Bio obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT platform to support the development of Be Bio’s BCMs programs.
Lead Product(s): B Cell-based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Be Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 02, 2024
Details:
Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs, including WU-CART-007, for hematologic and solid tumor cancers.
Lead Product(s): WU-CART-007
Therapeutic Area: Oncology Product Name: WU-CART-007
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Wugen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 30, 2024
Details:
Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel, a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer.
Lead Product(s): Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: PBCAR0191
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Imugene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 23, 2024
Details:
Under the terms of the agreement, Lion TCR obtains worldwide non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for the development of new TCR-T cell therapies for patients with solid tumors.
Lead Product(s): TCR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lion TCR
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 03, 2024
Details:
Under the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform, to develop a new class of differentiated, one-time, potentially curative genetic therapies.
Lead Product(s): Genetic Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Prime Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 01, 2023
Details:
Vittoria will obtain rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform which will support its Senza5 technology to enhance efficacy of T-cell therapies including, Viper 101, a gene-edited, autologous, dual-population cell therapy for T-cell lymphoma.
Lead Product(s): Viper 101
Therapeutic Area: Oncology Product Name: Viper 101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vittoria Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 10, 2023
Details:
Under the agreement, Walking Fish will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases.
Lead Product(s): B Cell-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Walking Fish Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 04, 2023
Details:
CAT-248 is a CAR-NK cell therapy targeting CD70 positive tumors. CAT-248 has been engineered with four functional modifications: an optimized CAR that targets CD70, an IL-15 cytokine, a TME-switch, and the elimination of CD70 expression to enable scalable manufacturing.
Lead Product(s): CAR-NK Cell Therapy
Therapeutic Area: Oncology Product Name: CAT-248
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Catamaran Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 03, 2023
Details:
Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Curamys
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 05, 2022
Details:
Under the terms of the agreement, Vertex obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in the development of its CRISPR/Cas9-based gene-edited therapy (exa-cel, formerly known as CTX001).
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Genetic Disease Product Name: Exa-cel
Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
